Cargando…
The role of the proteasome in AML
Acute myeloid leukemia (AML) is deadly hematologic malignancy. Despite a well-characterized genetic and molecular landscape, targeted therapies for AML have failed to significantly improve clinical outcomes. Over the past decade, proteasome inhibition has been demonstrated to be an effective therape...
Autores principales: | Csizmar, C M, Kim, D-H, Sachs, Z |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223148/ https://www.ncbi.nlm.nih.gov/pubmed/27911437 http://dx.doi.org/10.1038/bcj.2016.112 |
Ejemplares similares
-
The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011) -
Role of proteasomes in disease
por: Dahlmann, Burkhardt
Publicado: (2007) -
Role of Proteasomes in Inflammation
por: Goetzke, Carl Christoph, et al.
Publicado: (2021) -
Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022) -
The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
por: Orlowski, Robert Z, et al.
Publicado: (2003)